NCT04313244View on ClinicalTrials.gov

Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

614

Participants

Timeline

Start Date

May 15, 2021

Primary Completion Date

February 21, 2022

Study Completion Date

July 19, 2022

Conditions
Dengue Fever
Interventions
BIOLOGICAL

9vHPV Vaccine

9vHPV intramuscular injection

BIOLOGICAL

Dengue Tetravalent Vaccine (TDV)

TDV subcutaneous injection

Trial Locations (4)

10330

King Chulalongkorn Memorial Hospital, Bangkok

10400

The Hospital for Tropical Diseases, Bangkok

10700

Siriraj Hospital, Bangkoknoi

12121

Thammasat University Hospital, Pathum Thani

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY